What is Seven Bridges?
Founded in 2009, Seven Bridges operates a cloud-based platform designed for rapid, collaborative analysis of millions of genomes and other forms of biomedical data. Its technology empowers thousands of researchers across government, biotech, pharmaceutical, and academic institutions. Notably, Seven Bridges supports three of the world's largest genomics projects: the U.S. National Cancer Institute's Cancer Genomics Cloud pilot, the Million Veteran Program, and Genomics England's 100,000 Genomes Project. As the NIH's only commercial Trusted Partner, Seven Bridges is instrumental in authenticating and authorizing access to one of the largest cancer genomics datasets globally. Recognized by MIT Technology Review as one of the world's smartest companies, Seven Bridges has established a global presence with offices in Cambridge, Mass.; Belgrade; London; Istanbul; and San Francisco.
How much funding has Seven Bridges raised?
Seven Bridges has raised a total of $63.3M across 4 funding rounds:
Grant
$2.9M
Series A
$45M
Debt
$350K
Series C
$15M
Grant (2015): $2.9M with participation from Genomics England
Series A (2016): $45M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series C (2021): $15M, investors not publicly disclosed
Key Investors in Seven Bridges
Genomics England
Genomics England, established in 2013, is a UK-based entity focused on advancing genomic healthcare through research and the application of genomic medicine. Their involvement highlights a commitment to large-scale genomic initiatives.
PPP
Public-Private Partnership
What's next for Seven Bridges?
The substantial enterprise-level funding and recent strategic investment signal a period of accelerated expansion and innovation for Seven Bridges. This capital infusion is expected to bolster the company's capabilities in large-scale genomic data analysis, further solidifying its position as a leader in precision medicine and drug development. The company's ongoing work with major governmental and research initiatives suggests a continued focus on deepening its impact in critical areas of healthcare research, potentially leading to new platform developments and expanded collaborations. The strategic nature of the recent financing indicates a strong alignment with investor goals for market penetration and technological advancement.
See full Seven Bridges company page
